This is the protocol for a review and there is no abstract. The objectives are as follows:
The primary objective of this study will be to evaluate the efficacy of interleukin-2 (IL-2) as maintenance therapy in patients with acute myeloid leukaemia (AML) who have achieved first complete remission (CR).
If you can't find a tool you're looking for, please click the link at the top of the page to "Go to old article view". Alternatively, view our Knowledge Base articles for additional help. Your feedback is important to us, so please let us know if you have comments or ideas for improvement.